CONCLUSIONS: As expected, the five MG Symptoms PRO scales, which incorporate additional concepts such as physical fatigue, had stronger correlations with comparable concepts in MG-ADL and weaker correlations with QMG likely resulting from comparing patient- and clinician-reported data with different recall times. MG Symptoms PRO can complement existing MG-specific outcome measures to provide a granular… →

CONCLUSIONS: INFRONT-3 is designed to provide evidence of efficacy and safety for latozinemab, a potential first-in-class approach for treating FTD-GRN in a representative population spanning disease severity. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Carter has received personal compensation for serving as… →

CONCLUSIONS: These findings underscore the importance of baseline neuropsychological scores and plasma P-tau217 in predicting cognitive decline. Predictive models using these practical measures can improve clinical trial design and optimize participant selection, enhancing the effectiveness of interventions. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.… →

CONCLUSIONS: Bemdaneprocel demonstrated a favorable safety profile and trended toward clinical benefit or stability through 24 months post transplantation. All participants have enrolled in a continued-evaluation study (NCT05897957). These results support the ongoing development of bemdaneprocel in a Phase 3 trial to evaluate efficacy and safety in people with PD. Disclosure: The institution of Dr.… →

CONCLUSIONS: We saw no signal for worsening of supine hypertension on ampreloxetine in patients with alpha-synucleinopathies and nOH. This suggests that, if the ongoing phase 3 study confirms safety and efficacy, ampreloxetine may be the first drug to treat nOH without exacerbating supine hypertension, which should not worsen intravascular volume loss overnight or add to… →